The Other Shoe Drops: uniQure Shares Plans To Submit Licensing Application With The FDA for AMT-130

uniQure shared in a press release on June 17, 2026 that the Food and Drug Administration (FDA) has agreed the 3-year data from their Phase I/II study can serve as the basis for a Biologics License Application (BLA), the application which could lead to the approval of their drug, AMT-130 in the United States. This update follows a Type B meeting with the agency, as the company continues to seek approval of their gene therapy drug designed for the treatment of Huntington’s disease (HD). While this is a major step forward, it does not mean the drug has been approved or is broadly accessible yet. Here’s what we know, and what we are still waiting to learn.

The Backstory

AMT-130 has had one of the longest and most closely followed development journeys of any HD therapy currently in clinical testing. By early 2021, the first participants had received the experimental gene therapy, marking the first time a gene therapy for HD entered human clinical trials. This landmark moment for the HD community was built upon years of study in different animal models to study this drug and assess its safety. 

Unlike many other huntingtin-lowering approaches that require repeat dosing, AMT-130 has the potential to last a lifetime from just one dose. During a brain surgery procedure, a harmless virus is injected that delivers genetic instructions intended to lower huntingtin levels in cells in a part of the brain called the striatum. 

We have been closely tracking the programme since then, as it expanded across the US and Europe, advanced with different dose cohorts, and generated the first long-term safety and biomarker data, steadily building a picture of both the challenges and promise of this approach. 

The story reached a major milestone in September 2025 when uniQure announced topline results from its Phase I/II study showing that participants receiving high-dose AMT-130 seemed to experience slower disease progression than matched individuals from natural history datasets. This was the first time any drug had been described as slowing down HD in people, and although the analysis uniQure used was not without critics, the news was nonetheless cause for cautious optimism. 

However, despite previous alignment with the FDA about this trial design and the measurements to be made, we then received news that the agency no longer held this view and the path forward for AMT-130 regulatory approval became murky. Despite this significant set back, uniQure continued forward with applications planned for submission to other regulators. 

How things might move forward with the FDA was less clear though, until today’s press release from uniQure. Let’s get into what we have learned. 

Today’s Update

Today, on June 17, 2026, uniQure shared a press release with an update from their recent Type B meeting with the FDA. In March, uniQure announced that they hoped to use this meeting to further discuss development of AMT-130 for the treatment of HD and possible clinical trial designs to move that forward. Here’s what came out of that meeting:

FDA agreed the existing 3-year data is enough to file 

Through uniQure, we’ve learned that the FDA has agreed that the 3-year analysis from the Phase I/II study would be acceptable as the primary basis for a BLA seeking approval of AMT-130, which they hope to submit by Q3 of 2026. This sets our sights on September of this year to hear more about possible licensing approval for AMT-130 in the US.

This gives us a hopeful signal that the agency views the data uniQure has already collected, comparing treatment cohorts against the Enroll-HD natural history dataset, as sufficient to move forward with a submission.

A confirmatory study is still required, and its design isn’t locked in yet 

Before uniQure submits the BLA, the FDA will align with the company on the design of a future confirmatory study. This study will only be run if the BLA is approved and will be used to verify the drug’s benefit in slowing progression of HD. 

The press release specifically mentions considering a “concurrent control on standard-of-care therapy instead of a sham procedure.” This is worth unpacking, because it’s easy to misread: “concurrent” control could mean a comparison group of patients enrolled in real time, receiving standard medical care, rather than a comparison built from a natural history database like Enroll-HD (which is how current cohorts going in to the BLA were analyzed). 

If this design holds, it could mean that participants in the confirmatory study would not need to undergo a sham brain surgery, a meaningful change from the original Phase I/II study design, which did include a sham surgery arm. The FDA’s original request for a sham surgery was a recent sticky point (understandably!) with the HD community. That said, this is provisional, not finalized, and the details still need to be worked out with the FDA before the study begins.

What approval would mean

If the BLA is accepted, this would mean that AMT-130 is approved for marketing in the US as a drug designed to treat HD. It could be sold to people with HD while the confirmatory study is ongoing. However, if the confirmatory study fails to verify the hoped-for clinical benefit, the agency has the authority to withdraw AMT-130 from the market. 

The press release doesn’t specifically spell out this contingency, but it’s a typical feature of how a drug would move forward using the confirmatory study design. 

The Timeline

We want to generate as clear of a picture as possible of what this timeline could look like:

1. uniQure aligns with the FDA on the confirmatory study design. This will include if they can use a natural history as a control group and/or if a sham control group is requested. 
2. uniQure applies for a BLA with the FDA by Q3 2026
3. If the BLA is approved, uniQure will run a confirmatory study while AMT-130 is being licensed 
4. If the confirmatory study is successful, AMT-130 will continue to be marketed for the treatment of HD. However, if the confirmatory study suggests AMT-130 is not slowing progression of HD signs and symptoms, the drug will get withdrawn from the market.

There are several contingencies built into this timeline, including if the BLA is accepted and if the confirmatory study is successful. So while this represents a real and welcome step forward, it does not yet mean that AMT-130 has been accepted for licensing or that the drug is broadly available to the HD community, in the US or elsewhere. 

What We’re Watching

There are a few outstanding questions that we’re keeping a close eye on that will help shape what happens next:

• What exactly will the confirmatory study’s control group look like, and will participants need to undergo any kind of surgical procedure at all?
• Will the FDA’s formal meeting minutes, expected to be delivered to uniQure within the next 30 days, add nuance beyond what’s in today’s press release?
• Will the BLA stay on track for Q3 of 2026, and how long might the FDA review take from there?

We’ll continue to track updates from uniQure, the FDA, and each of these questions as more information becomes available. 

Momentum Generates Movement

While it’s not exactly clear what motivated this shift in the FDA’s position, it follows a lot of behind-the-scenes (and sometimes front-and-center!) advocacy efforts by the community as well as several changes in senior agency leadership over the past year. 

Whatever tipped the sales, we welcome a community partnership with regulatory agencies that will help us cross the finish line toward the first disease modifying drug for HD. That would never be possible without the persistence and effort of everyone across the HD community who gives their time, energy, and effort to participate in clinical trials. For that, and everything you do to help us advance medicines for HD, we thank you.

Summary

• The FDA has agreed that uniQure’s existing 3-year Phase I/II data can serve as the basis for a Biologics License Application (BLA) seeking accelerated approval of AMT-130 in the United States
• uniQure plans to submit that BLA by Q3 2026
• A confirmatory study is still required, and its design (including the control group) will be worked out with the FDA before submission. While it may not require a sham surgery, but that’s not yet finalized
• If approval is granted, AMT-130 could be marketed while the confirmatory study runs, but the drug could be withdrawn later if that study doesn’t confirm a clinical benefit
• This is a real and welcome step forward, but several contingencies remain before AMT-130 is approved or available to the HD community